{
    "id": 50750,
    "name": "splenic marginal zone lymphoma",
    "source": "DOID",
    "definition": "A marginal zone B-cell lymphocyte located_in the spleen comprised of B-cells in place of white pulp. [url:http\\://en.wikipedia.org/wiki/Splenic_marginal_zone_lymphoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0050750",
    "evidence": [
        {
            "id": 6001,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ST7612AA1 inhibited proliferation of splenic marginal zone lymphoma cell lines in culture (PMID: 25671299).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3989,
                "therapyName": "ST7612AA1",
                "synonyms": null
            },
            "indication": {
                "id": 50750,
                "name": "splenic marginal zone lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5200,
                    "pubMedId": 25671299,
                    "title": "Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25671299"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19111,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "MYD88 mutations aid in the diagnosis of splenic marginal zone lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 1917,
                "profileName": "MYD88 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50750,
                "name": "splenic marginal zone lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19112,
            "approvalStatus": "Guideline",
            "evidenceType": "Diagnostic",
            "efficacyEvidence": "BRAF mutations aid in the diagnosis of splenic marginal zone lymphoma (NCCN.org).",
            "molecularProfile": {
                "id": 465,
                "profileName": "BRAF mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 50750,
                "name": "splenic marginal zone lymphoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT03601819",
            "title": "Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2006,
                    "therapyName": "Pacritinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03696784",
            "title": "Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5992,
                    "therapyName": "Rimiducid",
                    "synonyms": null
                },
                {
                    "id": 7976,
                    "therapyName": "Bendamustine + Fludarabine + iC9/CAR.19/IL15-Transduced CB-NK",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04223765",
            "title": "Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 9229,
                    "therapyName": "Bendamustine + CAR.k.28 cells + Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 9230,
                    "therapyName": "CAR.k.28 cells + Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        }
    ]
}